Free Trial

Cormark Comments on Vitalhub's FY2025 Earnings (TSE:VHI)

Vitalhub logo with Medical background

Key Points

  • Cormark has estimated that Vitalhub's earnings per share (EPS) for FY2025 will be $0.09, significantly lower than the current consensus estimate of $0.23 per share.
  • Several research firms have given Vitalhub stock buy and outperform ratings, with price targets ranging from C$14.00 to C$16.00.
  • Vitalhub shares recently increased by 4.7%, and the company currently has a market cap of C$730.79 million.
  • MarketBeat previews the top five stocks to own by October 1st.

Vitalhub Corp. (TSE:VHI - Free Report) - Analysts at Cormark issued their FY2025 earnings per share (EPS) estimates for shares of Vitalhub in a research report issued to clients and investors on Monday, August 11th. Cormark analyst G. Fairweather expects that the company will post earnings per share of $0.09 for the year. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share. Cormark also issued estimates for Vitalhub's FY2026 earnings at $0.29 EPS and FY2027 earnings at $0.42 EPS.

VHI has been the subject of several other reports. Raymond James Financial raised their target price on Vitalhub from C$14.50 to C$15.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 12th. TD Securities increased their price target on Vitalhub from C$15.00 to C$16.00 and gave the company a "buy" rating in a research note on Monday, August 11th. Scotiabank increased their price target on Vitalhub from C$14.00 to C$14.50 and gave the company an "outperform" rating in a research note on Friday, June 20th. National Bankshares set a C$14.00 price target on Vitalhub and gave the company an "outperform" rating in a research note on Tuesday, June 10th. Finally, National Bank Financial raised Vitalhub to a "strong-buy" rating in a research note on Monday, June 9th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of C$13.75.

Get Our Latest Research Report on VHI

Vitalhub Price Performance

Shares of TSE VHI traded up C$0.15 during mid-day trading on Wednesday, hitting C$12.90. 180,106 shares of the stock traded hands, compared to its average volume of 149,530. Vitalhub has a twelve month low of C$7.62 and a twelve month high of C$14.64. The company has a market cap of C$697.79 million, a PE ratio of 209.81, a price-to-earnings-growth ratio of 1.18 and a beta of 1.26. The firm has a 50 day simple moving average of C$12.13 and a two-hundred day simple moving average of C$10.92.

About Vitalhub

(Get Free Report)

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.

Featured Articles

Earnings History and Estimates for Vitalhub (TSE:VHI)

Should You Invest $1,000 in Vitalhub Right Now?

Before you consider Vitalhub, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.

While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.